Federal Register / Vol. 88, No. 184 / Monday, September 25, 2023 / Notices 65691 

which is submitted annually by plans. 

Additionally, the proposed collection 

will request information to be split out 

by the authority under which each plan 

offers the benefits (mandatory, optional, 

mandatory-SSBCI, mandatoryUniformity Flexibility). Form Number: 

CMS–10261 (OMB control number: 

0938–1054); Frequency: Annually; 

Affected Public: Business or other forprofits; Number of Respondents: 743; 

Total Annual Responses: 6,687; Total 

Annual Hours: 187,979. (For policy 

questions regarding this collection 

contact Lucia Patrone at (410) 786– 

8621). 

Dated: September 20, 2023. 

William N. Parham, III, 

Director, Paperwork Reduction Staff, Office 

of Strategic Operations and Regulatory 

Affairs. 

[FR Doc. 2023–20739 Filed 9–22–23; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2023–N–2079] 

Hospira, Inc., et al.; Withdrawal of 

Approval of Eight Abbreviated New 

Drug Applications; Correction 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; correction. 

SUMMARY: The Food and Drug 

Administration (FDA) is correcting a 

notice entitled ‘‘Hospira, Inc., et al.; 

Withdrawal of Approval of Eight 

Abbreviated New Drug Applications’’ 

that appeared in the Federal Register of 

June 2, 2023. The document announced 

the withdrawal of approval (as of July 3, 

2023) of eight abbreviated new drug 

applications (ANDAs) from multiple 

applicants. The document indicated that 

FDA was withdrawing approval of 

ANDA 077029, Calcipotriene Solution, 

0.005% after receiving a withdrawal 

request from Tolmar, Inc., 701 Centre 

Ave., Fort Collins, CO 80526. Before 

FDA withdrew the approval of this 

ANDA, Tolmar, Inc. informed FDA that 

it did not want the approval of the 

ANDA withdrawn. Because Tolmar, Inc. 

timely requested that approval of ANDA 

077029 not be withdrawn, the approval 

is still in effect. This document corrects 

that error. 

FOR FURTHER INFORMATION CONTACT: 

Martha Nguyen, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 75, Rm. 1676, 

Silver Spring, MD 20993–0002, 240– 

402–6980, Martha.Nguyen@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of Friday, June 2, 2023 

(88 FR 36320), in FR Doc. 2023–11744, 

the following correction is made: 

On page 36321, in the table, the entry 

for ANDA 077029 is removed. 

Dated: September 20, 2023. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2023–20742 Filed 9–22–23; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2023–N–0853] 

Yogurt Products Deviating From 

Standard of Identity; Amendment of 

Temporary Marketing Permit 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA or we) are 

amending Chobani, LLC’s temporary 

permit to market test lower-fat yogurt 

products. The temporary permit is 

amended to allow the use of the test 

product as an ingredient in other 

nonstandardized food applications 

including drinkable beverages, dips, and 

sauces. This amendment will allow the 

applicant to continue to test market the 

test product, as ingredients, in whole or 

in part, in other nonstandardized foods 

and collect data on consumer 

acceptance of the test product. 

FOR FURTHER INFORMATION CONTACT: 

Marjan Morravej, Center for Food Safety 

and Applied Nutrition (HFS–820), Food 

and Drug Administration, 5001 Campus 

Dr., College Park, MD 20740, 240–402– 

2371. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of March 28, 2023 (88 

FR 18322), we issued a notice 

announcing that we issued a temporary 

permit to Chobani, LLC, 200 Lafayette 

St., New York, NY 10012, to market test 

lower-fat yogurt products deviating from 

the general definition and standard of 

identity for yogurt with modified 

milkfat and fat-containing flavoring 

ingredients, and yogurt deviating from 

the yogurt standard of identity by using 

ultrafiltered nonfat milk as a basic dairy 

ingredient. The permit allowed for the 

test product to be manufactured at 3450 

Kimberly Rd. East, Twin Falls, ID 83301 

and 669 County Rd. 25, New Berlin, NY 

13411. 

We issued the permit to facilitate 

market testing of products that deviate 

from the requirements for the basic 

dairy ingredient provision of the yogurt 

standard of identity under 21 CFR 

131.200(b). 

Under our regulations at 21 CFR 

130.17(f), we are amending the 

temporary permit issued to Chobani, 

LLC, to allow the test product to be used 

as ingredients, in whole or in part, in 

other nonstandardized foods. All other 

conditions and terms of this permit 

remain the same. 

Dated: September 20, 2023. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2023–20736 Filed 9–22–23; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Heart, Lung, 

and Blood Institute Initial Review 

Group, Mentored Patient-Oriented 

Research Study Section, October 26, 

2023, 10:00 a.m. to October 27, 2023, 6 

p.m., National Institutes of Health, 

Rockledge 1, 6705 Rockledge Drive, 

Bethesda, MD 20892, which was 

published in the Federal Register on 

September 14, 2023, FR Doc 2023– 

19907, 88 FRN 63115. 

The National Heart, Lung, and Blood 

Institute Initial Review Group, 

Mentored Patient-Oriented Research 

Study Section meeting is being 

amended due to a change of the meeting 

time formats. The meeting will be held 

on October 26, 2023, from 9:00 a.m. to 

October 27, 6:00 p.m. This meeting will 

be a video assisted meeting, and closed 

to the public. 

Dated: September 18, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20648 Filed 9–22–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 


ddrumheller on DSK120RN23PROD with NOTICES1
65692 Federal Register / Vol. 88, No. 184 / Monday, September 25, 2023 / Notices 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel; K99–U24–R13 SEP. 

Date: November 3, 2023. 

Time: 2:30 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Human Genome Research Institute, 

6700B Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Sarah Jo Wheelan, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Human Genome Research 

Institute, National Institutes of Health, 6700B 

Rockledge Drive, MSC 6908, Bethesda, MD 

20892, (301) 402–8823, wheelansj@nih.gov. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel; SEP–1 K99 HG013541–01 Member 

Conflict. 

Date: November 3, 2023. 

Time: 6:15 p.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Human Genome Research Institute, 

6700B Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Sarah Jo Wheelan, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Human Genome Research 

Institute, National Institutes of Health, 6700B 

Rockledge Drive, MSC 6908, Bethesda, MD 

20892, (301) 402–8823, wheelansj@nih.gov. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel; Diversity Centers. 

Date: November 16, 2023. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Human Genome Research Institute, 

6700B Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Rudy O. Pozzatti, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Human Genome Research 

Institute, National Institutes of Health, 6700B 

Rockledge Drive, MSC 6908, Bethesda, MD 

20892, (301) 402–8739, pozzattr@

mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: September 18, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20647 Filed 9–22–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

Individually Measured Phenotypes to 

Advance Computational Translation in 

Mental Health (IMPACT–MH) (U01 & U24). 

Date: October 19–20, 2023. 

Time: 9:00 a.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard Rockville, MD 20852, (Virtual 

Meeting). 

Contact Person: Rebecca Steiner Garcia, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

Neuroscience Center, 6001 Executive Blvd., 

Bethesda, MD 20892–9608, 301–443–4525, 

steinerr@mail.nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

ALACRITY: Advanced Laboratories for 

Accelerating the Reach and Impact of 

Treatments for Youth and Adults with 

Mental Illness Centers. 

Date: October 19, 2023. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Regina Dolan-Sewell, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

Neuroscience Center, 6001 Executive Blvd., 

Bethesda, MD 20852, (240) 796–6785, 

regina.dolan-sewell@nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

BRAIN Initiative: Brain Behavior 

Quantification and Synchronization—Data 

Coordination and Artificial Intelligence 

Center. 

Date: October 20, 2023. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Evon Abisaid, Ph.D., 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

6001 Executive Blvd., Bethesda, MD 20852, 

301–827–0399, ereifejes@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.242, Mental Health Research 

Grants, National Institutes of Health, HHS) 

Dated: September 18, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20652 Filed 9–22–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Biological Chemistry 

and Macromolecular Biophysics Integrated 

Review Group; Macromolecular Structure 

and Function C Study Section. 

Date: October 12–13, 2023. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: James W. Mack, Ph.D., 

Scientific Review Administrator, Center for 

Scientific Review, National Institutes of 


ddrumheller on DSK120RN23PROD with NOTICES1